Search Results | DrugBank Online

Displaying drugs 14326 - 14350 of 15057 in total

Elinzanetant

Elinzanetant is under investigation in clinical trial NCT05099159 (A Study to Learn More About How Well Elinzanetant Works and How Safe It Is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)).

Investigational

Matched Description: … investigation in clinical trial NCT05099159 (A Study to Learn More About How Well Elinzanetant Works and …

2-Phenethyl-2,3-Dihydro-Phthalazine-1,4-Dione

Experimental

3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine

Experimental

5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine

Experimental

5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine

Experimental

PQ-10

Experimental

5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine

Experimental

MK-0812

MK0812 has been used in trials studying the treatment of Relapsing-Remitting Multiple Sclerosis.

Investigational

(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene

(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene is a solid. This compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. Known drug targets of (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and naphthalene 1,2-dioxygenase subunit alpha.

Experimental

Matched Description: … (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and …

Clocapramine

Clocapramine is an atypical antipsychotic of the imidobenzyl class which was introduced in Japan in 1974 for the treatment of schizophrenia. In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic. Clocapramine has been implicated in at least one strange death,...

Experimental

Matched Description: … to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and …

REP8839

REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

Investigational